



(51) International Patent Classification:

A23D 9/00 (2006.01) A23K 1/16 (2006.01)
A23D 9/007 (2006.01) A23D 9/013 (2006.01)
A23L 1/30 (2006.01)

(21) International Application Number:

PCT/EP2014/071418

(22) International Filing Date:

7 October 2014 (07.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13187560.1 7 October 2013 (07.10.2013) EP

(71) Applicant: SAELE INVEST & CONSULTING AS
[NO/NO]; Bergheimveien 15 A, NO-1367 Snarøya (NO).

(72) Inventors: HOFSTRA, Harmen; Faunalaan 89, NL-3972
PP Driebergen (NL). SAELE, Ørjan; c/o Saele Invest &
Consulting AS, Bergheimveien 15 A, NO-1367 Snarøya
(NO). EIDE, Ola; Hoslegata 3, NO-1356 Bekkestua (NO).
SAGA, Linda Christine; Borgeåsveien 12, NO-3914
Porsgrunn (NO).

(74) Agent: PLOUGMANN & VINGTOFT A/S; Rued Lang-
gaards Vej 8, DK-2300 Copenhagen S (DK).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: EDIBLE LIPID COMPOSITION COMPRISING STEARIDONIC ACID AND OLIVE OIL



(57) Abstract: The present invention
relates to an edible lipid composition com-
prising olive oil and a stearidonic acid
component (SDA component) comprising
high amounts of SDA, such as at least 6%
by weight SDA.

Fig. 1

Edible lipid composition comprising stearidonic acid and olive oil

Technical field of the invention

The present invention relates to an edible lipid composition comprising olive oil
5 and a stearidonic acid component (SDA component), wherein said SDA component
comprises stearidonic acid in an amount of at least 6% by weight and wherein
said olive oil comprises polyphenols in an amount of at least 250 mg per kg olive
oil and wherein the ratio between the olive oil and the SDA component is from 3:8
to 3:2. Further, the present invention relates to a method of preparing such lipid
10 composition and the use of such lipid composition for use in preventing or
reducing the risk of developing cardiovascular diseases, coronary thrombosis, and
other inflammatory diseases such as atherosclerosis, cancer, diabetes, psoriasis,
arthritis, rheumatism and asthma, osteoporosis, and alzheimers.

15

Background of the invention

Life-style related health problems are becoming an increased threat to the
population. Atherosclerosis, cardiovascular diseases, cancer, diabetes are
examples of such life-style related conditions.

20

Atherosclerosis is the build-up of a waxy plaque on the inside of blood vessels and
may also be referred to as hardening of the arteries. Atherosclerosis, which may
also be termed arteriosclerosis, is a progressive process and is responsible for
most heart disease. The plaque deposits on the blood vessels will block the flow of
25 the blood and may therefore lead to blood thrombosis or other related diseases or
conditions.

Atherosclerotic injuries is formed when three circulation components, monocytes,
blood plates, and T-lymphocytes reacts with low-density lipoproteins (LDL-
30 cholesterol) and two cell types in the artery wall, endothelialcells (EC) and the
smooth musclecells (SMC). Thus, a high level of LDL-cholesterol in the blood
increases the risk of developing atherosclerosis; while high levels of high-density

lipoprotein (HDL-cholesterol) decreases the risk of develop coronary artery diseases, i.e. atherosclerosis.

The precursor of atherogenesis is recruitment of monocytes and lymphocytes from
5 the peripheral blood to intima in the vessel walls, a condition which is believed to be dependent of high levels of LDL. When LDL accumulates, bound lipid and protein becomes oxidized and glycosylated. Cells in the vessel wall seem to understand this change as a dangerous signal and ask for enhancement from the body's defense system. These processes seem to enhance an upregulation of
10 adhesion molecules on endocells, particularly the vascular cell adhesion molecule-1 (VCAM-1) and the intracellular adhesion molecule-1 (ICAM-1). So are the recruitment of monocytes and lymphocytes initiated, which leads to increased transmigration of monocytes, up-regulated exposure of adhesion molecules on the endothel, and production and release of chemical attractant substances. Available
15 modified LDL is necessary for the further development of macrophages into foam cells, which is the main reason in development of fat deposits under the vessel walls endothel.

As mentioned above, it is known that monocytes play a central role in the early
20 phase of atherogenesis. One of the first events in the atherosclerotic process is mobilisation of monocytes into intima. Exactly how the functional characteristics of circulating monocytes are related to atherogenesis is complex and not fully understood in details, but that hyperactive monocytes are crucial in relation to rheumatism, psoriasis and other inflammatory diseases is generally known.

25

Thus, the levels of LDL and HDL in the blood are known to play a role on developing cardiovascular diseases and other inflammatory diseases. Further, it is know that ingestion of the long chained polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docoxhexaenoic acid (DHA) can increase the HDL
30 levels in blood and therefore have an influence in preventing development of these types of diseases.

During the last decades, intake of Omega-6 polyunsaturated fatty acids have increased in the Western diet, causing an imbalance in the Omega-6/ Omega-3
35 ratio. The arachidonic acid/eicosapentaenoic acid (AA/EPA) ratio of cell

membranes is a mirror of the Omega-6/Omega-3 ratio in our diet. This ratio has constantly increased in Europe from 1:1 in 1850 to 15:1 or more in 2000, which is believed to affect our health in a negative way, such as increased susceptibility to lifestyle related health problems. Target for a healthy Omega-6/Omega-3 fatty acid balance should be 1:1-3:1. The inventors internal results of more than 17 thousand people in the Nordic countries show that the AA/EPA ratio of circulating red blood cells are around 12:1 in average, and the average omega-3 index (EPA+DHA) is 4 %. The recommended ratio is 1:1-3:1 and omega-3 index above 8 % for optimal health.

10

Yet our body cannot generate Omega-3s itself. Instead they must be obtained through your diet. The body must convert the short-chain version, alpha-linolenic acid (ALA), which is present in high amount in plant oils, to a long-chain version (EPA, DHA) to make use of it, but this conversion of ALA to EPA and DHA does not happen efficiently. Thus, the body has a need of supply of the long chained omega-3 fatty acids, EPA and DHA from other sources than ALA in plant oils.

It is an overall impression that dietary intakes of long chain omega-3 fatty acids are well below current recommended levels for optimal cardiovascular health. Fish and fish oil contains high levels of EPA and DHA and whilst an adequate intake of the long chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can be achieved by eating fatty fish at least 1-2 times per week, (equivalent to 250-500 mg per day of EPA and DHA), the majority of the population fails to achieve such intake.

25

A recommended amount of EPA and DHA may be obtained from fish or fish oil, which can prevent development of cardiovascular disease and other lifestyle related conditions. However, for vegetarians and vegans fish or fish oil is not an option and obtaining effective amount of EPA and DHA can therefore be a challenge. In India, for example, about 40 % of the population are vegetarians and therefore there is a need for a supplement of EPA and DHA not arriving from animals, including fish and fish oil. Further, fish oil has a characteristic smell and taste which is disliked by many. Thus, for this reason, an alternative to fish oil for obtaining EPA and DHA is also wished.

35

Hence, there is a need in the art for a composition which can supply the essential long chained polyunsaturated fatty acids, EPA and DHA, from a vegetable source in order for vegetarians and vegans to obtain the recommended amount of EPA and DHA the body needs, and a composition that will safeguard the oxidative
5 protection of EPA and DHA in the body in order to prevent oxidative stress.

Summary of the invention

Thus, an object of the present invention relates to providing a lipid composition which can ensure that the body obtains the daily amounts of EPA and DHA in a
10 protected manner, recommended by authorities in order to have an effect in preventing arteriosclerosis, cardiovascular diseases and other inflammatory diseases and wherein the composition is derived from plant sources and industrial sources of the Omega-3 component. Further, it is an object of the present invention to provide a lipid composition with an acceptable oxidative stability, i.e.
15 to protect both blood lipids and lipids in the lipid composition from oxidation.

In particular, it is an object of the present invention to provide a lipid solution that solves the above mentioned problems of the prior art.

20 Thus, one aspect of the invention relates to an edible lipid composition comprising olive oil and a stearidonic acid component (SDA component), wherein said SDA component comprises stearidonic acid in an amount of at least 6% by weight, and wherein said olive oil comprises polyphenols in an amount of at least 250 mg per kg olive oil and wherein the ratio between the olive oil and the SDA component is
25 from 3:8 to 3:2.

Another aspect of the present invention relates to a method of preparing the lipid composition according to the present invention, wherein the method comprises mixing of an olive oil comprising polyphenols in an amount of at least 250 mg/kg
30 and a SDA component comprising at least 6% SDA and optionally a further oil, preferably the olive oil is selected to protect long chain fatty acids from oxidizing.

Yet another aspect of the present invention is to provide an edible lipid

composition according to the present invention for use in administration to an animal or human for preventing or reducing the risk of developing cardiovascular diseases, coronary thrombosis, atherosclerosis, cancer, diabetes II, alzheimers, arthritis, rheumatism, osteoporosis, psoriasis or astma.

5

Brief description of the figures

Figure 1 shows the antioxidative effect of polyphenols on omega-3 fatty acids, EPA and DHA.

10 Detailed description of the invention

An aspect of the invention relates to an edible lipid composition comprising olive oil and a stearidonic acid component (SDA component), wherein said SDA component comprises stearidonic acid in an amount of at least 6% by weight, and wherein said olive oil comprises polyphenols in an amount of at least 250 mg per
15 kg olive oil and wherein the ratio between the olive oil and the SDA component is from 3:8 to 3:2.

Definitions:

Prior to discussing the present invention in further details, the following terms and
20 conventions will first be defined:

In the context of the present invention, mentioned percentages are by weight (weight/weight) percentages unless otherwise stated.

25 The term "and/or" used in the context of the "X and/or Y" should be interpreted as "X", or "Y", or "X and Y".

Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not.
30 Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 1 to 8, from 3 to 7, from 4 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth. All

references to singular characteristics or limitations of the present invention shall include the corresponding plural characteristic or limitation, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.

5

In the context of the present invention, the term "ratio" by weight (weight/weight) refers to the ratio between the weights of the mentioned compounds. For example, a composition comprising 60 g olive oil and 40 g SDA component would have a weight ratio which is equal to 60:40, which is equal to
10 3:2 or 1.5 (that is 3 divided with 2), corresponding to 60% olive oil and 40% SDA component. Similarly, a mixture of 50 g olive oil and 50 g SDA component would have a ratio by weight of olive oil and SDA component of 50:50, which is equal to 1:1 or 1 (that is 1 divided with 1).

15 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one skilled in the art.

Lipid composition:

The lipid composition according to the present invention is edible. By edible is
20 meant that the lipid composition is suitable for being consumed. Thus, the edible lipid composition is a composition suitable for being eaten by an animal or human being without being sick and/or violating internal organs.

In the context of the present invention, the term "lipid" refers to one or more
25 lipids and may be in the form of triglycerides, an oil, fatty acids, a concentrate or a fat.

By the term "lipid composition" is meant a composition comprising a substantial part of lipids, such as oils or fats.

30

In the context of the present invention, the term "substantially" refers to at least 90% lipids by weight, such as at least 90% oil by weight in the lipid composition. The lipid composition may for example comprise at an amount of at least 92% lipid by weight, such as at least 93% lipid by weight, for example at least 95%
35 lipid by weight, preferably at least 96% lipid by weight, such as at least 97% lipid

by weight, even more preferably at least 98% lipid by weight, such as 99% lipid by weight.

In an embodiment of the invention, the edible lipid composition is liquid.

5

In an embodiment of the invention, the lipid composition is an oil.

Preferably, the lipid composition is a mixture of two or more edible oils.

In another embodiment of the invention, the lipid composition is a concentrate or
10 a mixture of an oil and a concentrate, such as a mixture of olive oil and a concentrate comprising more than 6% SDA. The lipid composition may comprise one or more additional oils or fats or concentrates.

The lipid composition according to the present invention comprises olive oil and an
15 stearidonic acid component (SDA component), but may comprise other sources of lipids, fats, oils or free fatty acids in the form of ethylesters. In an embodiment of the invention, the lipid composition comprises one or more further oils.

The further lipid source than olive oil and SDA component may be any lipid or fat
20 source which is suitable for use in nutritional compositions to be fed to an animal or human, for example free fatty acids, or some vegetable fats or oils. Also monoglycerides, diglycerides, and/or triglycerides may be added as a further oil.

In an embodiment of the invention, a further oil, such as for example an alga oil,
25 may be added to the lipid composition according to the invention.

SDA component:

The lipid composition according to the present invention comprises a stearidonic acid component, hereinafter referred to as a SDA component. The SDA
30 component according to the present invention comprises stearidonic acid (SDA) in an amount of at least 6% by weight.

In an embodiment of the invention, the SDA component comprises SDA in an amount of at least 8% by weight, such as at least 10% by weight, preferably 10-
35 15% by weight, such as 12-15% by weight of the SDA component.

In another embodiment the SDA component comprises from 10 to 100% by weight SDA, such as from 10 to 80% by weight SDA, preferably from 12 to 70% by weight SDA, such as from 15 to 60% by weight SDA, preferably 15-40% by weight SDA.

Stearidonic acid (SDA) is an omega 3 fatty acid (C18:4) which can be converted to the beneficial polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Alpha-linolenic acid (ALA) which is present in plant oils in a high amount may also be converted to EPA and DHA, but the body is very poor in conversion of ALA to EPA and DHA. In general, ALA provides less than 4% of EPA and DHA in the fatty acid profile in the blood. On the contrary, it has been found out that SDA is more efficient converted to EPA and DHA. Without being bound by any theory, the inventors of the present invention believes that about 20-60% of SDA in an oil may be converted to EPA and DHA. This conversion rate is increased by addition of olive oil due to the protective effect of the olive oil on oxidative unstable omega-3 fatty acids. A better protection of omega-3 fatty acids will make more omega-3 available in the blood for in vivo health processes. When more SDA is available in the blood due to olive oils protective effect, the conversion rate of SDA to EPA and DHA will increase. Furthermore, sources with a high SDA content allows the body to convert SDA to EPA and DHA more efficiently, because it bypasses the rate limiting step of the ALA conversion process. ALA is the starting point of the conversion metabolism to EPA/DHA, where SDA is an intermediate in the same metabolism. When bypassing the first rate limiting step (ALA step), the conversion of the intermediate step (SDA step) to EPA and DHA is increased.

As explained above, EPA and DHA have anti-inflammatory effects and also beneficial effect on preventing cardiovascular diseases, especially in combination with olive oil rich in stabilizing antioxidants, such as polyphenols. EPA and DHA have been known to be present in high amounts in fish and fish oils.

From Harris, W. et al "*The Omega-3 index: a new risk factor for death from coronary heart disease Prevention Medicine*", 39, 2004, it is known that low intake or low blood levels of EPA and DHA are independently associated with increased risk of death from coronary heart disease (CHD). From Harris et al it is also

disclosed that fish or fish oil have been demonstrated to reduce CHD mortality at intakes of about 1 g/day.

Further, the European Food Safety Authority (EFSA) have concluded that it is safe
5 to consume up to 5 g per day of marine omega-3 fatty acids (EPA and DHA). EFSA is responsible for approving health claims based on scientific evidence for bioactive compounds. The following health claims for EPA and DHA have been approved by EFSA.

- 10 - DHA and EPA contributing to the normal function of the heart (0.25 g per day)
- DHA and EPA contributing to the maintenance of normal blood pressure (3 g per day)
- DHA and EPA contribute to the maintenance of normal blood triglycerides (2 g per day)
- 15 - DHA contributes to maintenance of normal blood triglyceride levels (2 g per day in combination with EPA)
- DHA contributes to maintenance of normal brain function (0.25 g per day)
- DHA contributes to the maintenance of normal vision (0.25 g per day)
- DHA maternal intake contributes to the normal brain development of the
20 foetus and breastfed infants (0.2 g DHA plus the daily recommended intake of omega-3 fatty acids (EPA and DHA) for adults which is 0.25 g per day).
- DHA maternal intake contributes to the normal development of the eye of the foetus and breastfed infants (0.2 g DHA plus the daily recommended intake of omega-3 fatty acids (EPA and DHA) for adults which is 0.25 g per
25 day).

However, an alternative to fish oils is wished to obtain the recommended intake of EPA and DHA, i.e. since vegetarians and vegans do not eat fish oil and since fish oil has a taste and smell disliked by many. There is an increasing demand for
30 vegetarians and vegans in need of supply of the beneficial polyunsaturated fatty acids EPA and DHA as an alternative to fish oil. Plant oil is not a suitable alternative as ALA present in plant oil is poorly converted to EPA and DHA. The conversion is so low that unsatisfactory high amounts of plant oil would be necessary to digest in order to provide a sufficient amount of converted EPA and

DHA. Thus, plant oils in general are not a suitable solution as an alternative to fish oil in supplying with EPA and DHA.

The SDA component may be in the form of either oil or a concentrate. In a preferred embodiment, the SDA component is in the form of oil. In an embodiment of the invention, the SDA component is from a vegetable source. For example, the SDA component may be Echium oil. Echium oil comprises a minimum of 12% SDA and has a SDA content between 12-15% by weight.

In another embodiment, the SDA component may be a concentrate comprising even higher amount of SDA, such as from 30-70% SDA, preferably about 40-60% SDA.

The SDA component may also be gene modified oil, for example a gene modified soyabean oil, comprising amounts of SDA in the range from 20-40 % SDA. Gene modified soybean oil is a biotechnological product that changes the oil composition in the soybean, in order to produce oils rich in SDA.

In a preferred embodiment, the SDA component is a natural oil. Consumers perceptibility has for the past years been increasing towards that ingredients consumed or digested should be natural, i.e. unmodified. Thus, it is an increasing demand to prepare products comprising all natural ingredients. Echium oil is a natural oil with a high content of SDA and is therefore very suitable as the SDA component according to the present invention. However, other natural oils may be used in the lipid composition according to the invention.

In an embodiment of the invention, the edible lipid composition comprises the SDA component in an amount of at least 25% by weight. The lipid composition may for example comprise the SDA component in an amount of at least 30% by weight, preferably at least 35% by weight, such as at least 40% by weight, even more preferably at least 45% by weight, such as at least 50% by weight, for example at least 55% by weight. In a preferred embodiment the lipid composition comprises more than 50% of the SDA component, i.e. the SDA component is the predominant lipid source in the lipid composition.

The edible lipid composition according to the present invention is preferably comprising the SDA component in an amount of from 25 to 80% by weight, for example from 30 to 75% by weight, preferably from 40 to 72% by weight, such as 45 to 70% by weight, such as from 50 to 70% by weight, even more preferably
5 from 55 to 65% by weight.

The present inventors have found out that when SDA is eaten as a food supplement in combination with olive oil, the SDA is converted to EPA and DHA in an amount of above 20% conversion. For EPA and DHA to have an effect in
10 preventing for example cardiovascular diseases a certain amount of EPA and DHA is necessary to be converted/obtained. Thus, a certain amount of SDA has to be ingested by a human being such that enough EPA and DHA can be produced to have an effect.

15 In an embodiment of the invention, the edible lipid composition comprises SDA in an amount of at least 3 g SDA per 100 ml lipid composition, such as at least 4 g SDA per 100 ml lipid composition, preferably at least 5g/100 ml, such as at least 6 g/100 ml. Around 3 g/day of SDA should be consumed to produce the same effect as 1 g/day of EPA, based on the calculated relative efficiency of red blood
20 cell incorporation of EPA. In a further embodiment, the lipid composition comprises at least 3% by weight SDA, such as at least 4% by weight of SDA, preferably at least 6% by weight SDA.

As discussed above, the SDA component may be derived from various sources,
25 including various vegetable sources. SDA is for example present in hemp seed oil. However, hemp seed oil comprises components which are wished to be avoided, for example hemp seed oil comprises cannabinoids. In Struempfer, R. E. et al "A positive Cannabinoids Workplace Drug test Following the Ingestion of Commercially Available Hemp Seed Oil", from Journal of Analytical Toxicology,
30 Vol. 21, July/August 1997 is described a study where a test person ingests a commercially available cold-pressed hemp seed oil twice a day for 4½ days. From urine tests, it was shown that the amount of 11-nor- Δ^9 -tetrahydrocannabinol carboxylic acid (9-THCA) increased in the urine from every amount of hemp seed oil ingested. 9-THCA is the major pharmacologically active component of the
35 marijuana plant (*Cannabis sativa*). Thus, by ingestion of hemp seed oil, a person

would be tested positive in a drug test which is wished avoided by the present invention.

Thus, in a preferred embodiment according to the present invention the SDA
5 component is not a hemp seed oil.

Besides, Hemp seed oil comprises a low amount of SDA, such as 1-2% which will result in a low conversion of the important fatty acid EPA. Furthermore, the linoleic acid (omega-6 fatty acid) content in hemp seed oil is high (50-70%) which
10 is not preferred. In the lipid composition according to the present invention, the omega-3 fatty acid content should be high, not the omega-6 fatty acid content. The omega-6 fatty acids, such as linoleic acid (LA – C18:2), gamma-linolenic acid (GLA – C20:3), and arachidonic acid (AA – C20:4) are not part of the pathway of conversion to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). On
15 the contrary omega-3 fatty acids may be converted to EPA and DHA, but different omega-3 fatty acids have different conversion rate. Where alpha-linolenic acid (ALA – C18:3) has been found to poorly convert to EPA, stearidonic acid (SDA – C18:4) has been found to have a high conversion rate to EPA.

20 Thus, in an embodiment of the invention, the SDA component comprises linoleic acid (LA) in amount below 10% by weight, such as below 8% by weight, preferably below 7% by weight.

However, the lipid composition according to the present invention should not be
25 free of omega-6 fatty acids, since some of the omega-6 fatty acids has other beneficial properties, e.g. gamma-linolenic acid (GLA) which is an essential fatty acid for the skin and has anti-inflammatory properties. GLA in combination with SDA also has the beneficial effect that blood cell EPA levels raise more effectively than EPA alone.

30

In an embodiment according to the invention the SDA component comprises omega-3 fatty acids in an amount of at least 4% by weight, such as from 4 to 40% by weight, for example from 5 to 35% by weight, such as from 10 to 30% by weight, preferably from 15 to 28% by weight.

35

In another embodiment of the present invention the SDA component comprises GLA in an amount of at least 5% by weight, preferably at least 8% by weight, such as 8-12% by weight.

- 5 GLA may for example be present in the SDA component in an amount from 5 to 20%, such as from 10 to 15%.

Olive oil:

The present invention comprises an olive oil.

10

The olive oil present in the lipid composition according to the invention is preferably present in an amount of at least 25% by weight. For example olive oil is present in an amount of at least 30% by weight, even more preferably at least 35% by weight, for example at least 40% olive oil by weight of the lipid

15 composition.

In a further embodiment, the lipid composition comprises olive oil in an amount of from 25 to 60% by weight of the lipid composition.

- 20 For example, the lipid composition comprises olive oil in an amount of from 25 to 60% by weight of the lipid composition, such as from 25 to 50% by weight, preferably from 30-45% by weight, such as from 35-45% by weight.

As discussed above stearidonic acid (SDA) is converted to EPA and DHA, which

- 25 are polyunsaturated fatty acids which are beneficial for a human being and can prevent the development of cardiovascular diseases and other life-style diseases. When SDA is administrated together with olive oil, a synergistic effect is obtained, such that olive oil protects SDA from oxidation in the oil and protects EPA and DHA converted from the SDA from oxidation in the human body which
30 can cause oxidative stress.

Thus, the more SDA present in the lipid composition, the more important the olive oil becomes, as it protects long chain fatty acids from oxidizing.

The protective effect of olive oil to prevent long chain fatty acids from oxidising is primarily due to the large content of polyphenols present in the olive oil, since polyphenols have an antioxidative effect. Different olive oils may have a different content of polyphenols and it is important for the present invention that the olive
5 oil comprises a high amount of polyphenol such as at least 250 mg polyphenols per kg olive oil. Polyphenols from olive oil contribute to the protection of blood lipids from oxidative stress. However, this effect is only for olive oils comprising 250 mg polyphenols per kg olive oil or more.

- 10 Besides from having a protective antioxidative effect, olive oil also increases the absorption of the SDA in the body and thus conversion of SDA to EPA and DHA.

The edible lipid composition according to the present invention must comprise both the SDA component and the olive oil with polyphenols in certain amounts. A
15 certain amount of SDA is important in order to be able to convert enough EPA and DHA for a the lipid composition can be administered to a human being in a preferred dosis. The preferred amount of omega-3, EPA and DHA, in the blood is above 8%. Further, olive oil with a certain amount of polyphenols should be comprised in the edible lipid composition according to the present invention, in an
20 amount such that the polyphenols provide an antioxidative effect and increase the absorption of SDA and thus the conversion of SDA to EPA and DHA.

In an embodiment of the invention, the edible lipid composition comprises olive oil and SDA component, wherein the ratio between the olive oil and SDA component
25 is from 2:8 to 3:2, preferably 3:8 to 1:1, such as from 1:2 to 1:1, preferably 4:6.

In a further embodiment of the invention, the edible lipid composition comprises olive oil and SDA component, wherein the ratio between the olive oil and the SDA component is from 3:8 to 3:2, such as from 4:8 to 4:3; preferably 5:8 to 4:4,
30 even more preferably from 4:6 to 6:4, such as from 45:55 to 50:50.

In a further embodiment, the olive oil polyphenols in the edible lipid composition is 100 to 350 mg polyphenols per kg SDA component (e.g. SDA oil), such as 125-300 mg polyphenol per kg SDA component, preferably 140 to 250 mg polyphenol
35 per kg SDA component. In a most preferred embodiment, edible lipid composition

comprises 150 to 200 mg polyphenols per kg SDA component. The optimum amount of polyphenols is 160 mg per kg SDA component.

Polyphenols in olive oil have an EFSA claim of protecting LDL particles from
5 oxidative damage when 5 mg hydroxytyrosol and derivatives are consumed daily. Also polyphenols are believed to have a role in preventing cardiovascular diseases, or at least reduce the risk of obtaining cardiovascular diseases, through an improvement in vascular function and a modulation of inflammation. Polyphenols are powerful anti-inflammation agents blocking inflammatory and
10 tissue-damaging enzymes. Polyphenols, such as those from olives (tyrosol, hydroxytyrosol etc.), also possess antioxidant properties protecting the cells and the blood lipids from oxidative stress proportionally to intake.

A high amount of polyphenols in an olive oil is also believed to increase the
15 amount of the high density lipoprotein fraction (HDL) which is the beneficial lipoprotein, as compared to olive oils with a low amount of polyphenols which provides a higher amount of the unwanted low density lipoprotein (LDL).

In an embodiment according to the present invention the olive oil is a virgin olive
20 oil, preferably an extra virgin olive oil. Extra virgin olive oil comprises a higher amount of polyphenols as compared to a virgin olive oil and a general olive oil.

In an embodiment of the invention, the lipid composition comprises olive oil comprising polyphenols in an amount of at least 250 mg/kg, and preferably at
25 least 300 mg/kg, such as at least 350 mg/kg.

In a preferred embodiment the olive oil comprises polyphenols in an amount of from 250 to 700 mg/kg, such as from 300 to 600 mg/kg, preferably from 300 to 550 mg/kg, such as from 350-550 mg/kg.

30

The amount of polyphenols in the olive oil is preferably in the range of 0.025 to 1% by weight and will preferably be in the range of 0.03 to 0.5% by weight such as in the range of 0.035 to 0.1% by weight.

Thus, the olive oil present in the edible lipid composition according to the present invention comprises polyphenol in the range of 0.030 to to 0.01% by weight.

Further, a combination of omega-3 long chained fatty acids and olive oil are

5 believed to help to subdue hyperactive monocyte cells in the immune system; while simultaneously counteracting oxidation of LDL-cholesterol. These are two major risk factors in the process of atherosclerosis. Thus, the composition according to the present invention comprising a combination of SDA and olive oil is believed to have an effect on atherosclerosis.

10

Besides from olive oil protects long chained fatty acids from oxidation and thus an improved conversion of SDA to EPA and/or DHA, olive oil contains other beneficial ingredients, such as high amounts of oleic acid, polyphenols and squalene.

15 For example, olive oil comprises oleic acid which is a monounsaturated omega-9 fatty acid (C18:1 n-9). By having a high amount of oleic acid present in the lipid composition, saturated fatty acids are beneficial replaced by the more beneficial oleic acid, which are favourable in the maintenance of normal LDL-cholesterol concentrations.

20

In an embodiment of the invention, the olive oil comprises at least 50% by weight oleic acid, such as at least by weight 55% oleic acid.

In a further embodiment of the invention, the lipid composition comprises oleic

25 acid in an amount of at least 10% by weight, preferably at least 20% by weight, such as at least 30% by weight.

Preferably the lipid composition comprises oleic acid in an amount of 10-70% by weight, such as 15-60% by weight oleic acid, preferably 20-55% by weight oleic

30 acid, for example 25-50% by weight oleic acid, such as 30-50% oleic acid by weight, even more preferably 35-45% oleic acid by weight

As mentioned earlier, polyphenols in olive oil has a protective effect against oxidation of EPA and DHA.

35

Olive oil contains several other health beneficial phenolic compounds, such as hydroxytyrosol and its secoiridic derivatives, and squalene. In addition, olive oil comprises tocopherols, sterols and other natural antioxidants

- 5 In an embodiment of the invention the edible lipid comprises olive oil comprising squalene in an amount of at least 200 mg/kg.

Squalene is preferably present as phytosqualene and present in the olive oil in an amount of from 200 mg/kg to 15 g/kg, such as from 300 mg/kg to 12 g/kg,

- 10 preferably in an amount of 400 mg/kg to 7 g/kg, such as 420 mg/kg to 1.2 g/kg, even more preferably from 450 mg/kg to 900 mg/kg, such as from 500 mg/kg to 800 mg/kg. In a preferred embodiment of the invention, the olive oil comprises 400-700 mg/kg squalene, preferably 400-450 mg/kg or 600-700 mg/kg squalene and in another embodiment the olive oil comprises from 800 mg/kg to 12 g/kg.

- 15 Squalene is the major hydrocarbon in olive oil and squalene is believed to improve health. Further, squalene provides an improved protection of the skin when digested, by protecting the skin surface from lipid peroxidation due to external sources. Squalenes protective effect is due to scavenging singlet oxygen generated by ultraviolet light.

20

In another embodiment of the invention, the olive oil comprises from 0.2 to 1.0% by weight squalene, such as from 0.3 to 0.9% by weight squalene, preferably from 0.4 to 0.8% by weight squalene, even more preferably from 0.5 to 0.75% by weight squalene, such as from 0.5 to 0.7% by weight squalene.

25

The polyphenols in olive oil, responsible for the stability and flavour, is endorsed with pharmacological properties. Phenolic compounds such as hydroxytyrosol and oleuropein in extra virgin olive oil are powerful antioxidants, both in the oil and in the body. They have bioactive properties that support the effects of the

- 30 Mediterranean diet being effective against oxidative stress associated health issues, including ageing, in a dose-dependent manner. Oxidative stress is defined as an imbalance between the oxidant and the antioxidant systems of the body in favour of the oxidants.

Olives and olive-derived products has beneficial health effects, particularly on the cardiovascular system. These benefits are due to a combination of a high content of oleic acid and a variety of polyphenol compounds found in olive-derived products. The phenolic compounds present in olive oil are strong antioxidants and radical scavengers. Virgin olive oil is well known for its high content of phenolic substances such as oleuropein, hydroxytyrosol (2-(3,4-dihydroxyphenyl)ethanol) and tyrosol (2-(4-hydroxyphenyl)ethanol). Hydroxytyrosol and its derivatives have shown in in vivo studies to have various biochemical roles including anti-inflammatory by inhibiting aggregation of platelets, prevent accumulation of the pro-aggregant thromboxane in human serum, inhibiting LOX activity and the production of pro-inflammatory molecules, such as leukotrienes, i.e. leukotriene B, and as antioxidants by prevent low density lipoprotein oxidation. The in vivo oxidation of LDL is linked to the formation of atherosclerotic plaques, which are postulated to contribute to the development of coronary heart disease.

15

A further oil:

The edible lipid composition according to the present invention may in an embodiment comprise one or more further oil. In some instances, the conversion of EPA and DHA from SDA may not be sufficient and then, a further oil comprising EPA and/or DHA may be included in the lipid composition in order for the amount of converted EPA and DHA from the lipid composition to meet recommended amounts of EPA and DHA made by authorities to have a healthy effect, i.e. to reduce the risk of develop cardiovascular diseases.

For general health and nutrition, most authorities are recommending 200 mg to 650 mg of EPA and DHA per day. European Food Safety Authority (EFSA) has recently approved the following quantitative claims for EPA and DHA (Omega-3 from fish):

- 2 g daily intake of DHA and EPA contributes to the maintenance of normal blood triglyceride concentrations. However, maximum 5 g EPA and DHA per day is recommended.
- 3 g daily intake of DHA and EPA contributes to the maintenance of normal blood pressures. However, maximum 5 g EPA and DHA per day is recommended.

According to EFSA it is safe to consume up to 5 gram Omega-3 daily.

35

In an embodiment of the invention, the lipid composition comprises from 25 to 40% by weight of the SDA component, 30 to 50% by weight of olive oil and 20 to 35% by weight of one or more further oil.

- 5 The further oil is preferably an oil comprising high amounts of EPA and DHA, such as 5% by weight or more EPA and DHA, preferably 7% by weight or more EPA and DHA, such as 10% by weight or more EPA and DHA, even more preferably 12% by weight or more EPA and DHA, such as 15% by weight or more of EPA and DHA. The further oil is preferably derived from a plant source such as an alga oil
- 10 or is ethylesters of EPA and/or DHA. The further oil may also preferably be in the form of ethylesters of EPA and DHA.

Alga oil:

- The further oil may be alga oil and in an embodiment of the invention, the further
- 15 oil is alga oil. Alga oil is a vegetarian source rich in DHA or EPA. Alga oil is beneficial to use in combination with an olive oil and SDA component in the lipid composition according to the present invention when there is a higher need for EPA than what can be converted from SDA. Alga oil is an ideal alternative to those who wish to avoid fish or soy products. By adding alga oil to the lipid composition
- 20 comprising olive oil and a SDA component, the lipid composition becomes a full nutrition as alternative to fish oil, as alga oil would add EPA or DHA such that the recommended values of EPA and DHA are met by the lipid composition. A pure alga oil is however not an alternative to fish oil, since alga oil contains either EPA or DHA and not the combination. Thus, alga oil is only suitable as an additive and
- 25 not a complete nutrition.

Ideally, vegetarians and vegans who are seeking to supplement with omega-3 for optimal heart health should seek oils containing EPA and DHA.

- 30 Alga oil may for example be present in the edible lipid composition according to the present invention in an amount of from 0 to 40% by weight, such as from 5 to 40% by weight, preferably from 10 to 35% by weight, such as from 15-30% by weight, even more preferably from 20 to 30% by weight.

In an embodiment of the invention, the lipid composition comprises from 25 to 40% by weight of the SDA component, 30 to 50% by weight of olive oil and 20 to 35% by weight of alga oil.

- 5 In a further embodiment of the invention, the lipid composition comprises 30% by weight of the SDA component, 40% by weight of olive oil and 30% by weight of alga oil.

Ethyl esters of EPA and/or DHA:

- 10 The further oil may be ethyl esters of EPA and/or DHA.

Ethyl esters of EPA and DHA are already digested fatty acids which are ready for absorption. Thus, ethylesters of EPA and/or DHA is an industrial source of omega-3 fatty acids.

- 15 EPA and DHA ethyl esters are a chemically modified form of fatty acids for the purpose of producing concentrates with high EPA and DHA content. During this process the glycerol backbone is removed from EPA and DHA. The free fatty acids are then esterified to form ethyl esters. Another method is to first use ethylation to concentrate EPA and DHA before the ethyl ester are broken down and

- 20 reconverted to triglyceride. Both these forms are classified as esters. In the ethyl ester, the fatty acids are esterified into a ethanol backbone.

- Some people have a poor absorption of triglycerides from the diet and some people do not have any absorption of triglycerides from the diet. The inventors of the present invention believes that this is due to a decrease or lack of lipases in
25 the small intestine or other problems in the small intestine. In order to overcome this problem om poor digestion of triglyceride, ethylesters of EPA and/or DHA can be added to the nutritional composition of the present invention.

- In a preferred embodiment the ethylesters of EPA and/or DHA is from a
30 vegetarian source.

- Ethylesters of EPA and/or DHA may for example be present in the edible lipid composition according to the present invention in an amount of from 0 to 40% by weight, such as from 5 to 40% by weight, preferably from 10 to 35% by weight,
35 such as from 15-30% by weight, even more preferably from 20 to 30% by weight.

In an embodiment of the invention, the lipid composition comprises from 25 to 40% by weight of the SDA component, 30 to 50% by weight of olive oil and 20 to 35% by weight of ethyl esters of EPA and/or DHA.

5

In a preferred embodiment, the lipid composition comprises both alga oil and ethyl esters of EPA/DHA, such as 5 to 40% by weight of alga oil and ethylesters of EPA and/or DHA, for example 2.5 to 20% by weight of alga oil and 2.5 to 20% by weight of estylesters of EPA and/or DHA.

10

Method:

The method of preparing the lipid composition according to the present invention comprises mixing of a an olive oil comprising polyphenols in an amount of at least 250 mg/kg and a SDA component comprising at least 6% SDA and optionally a

15 further oil, wherein the ratio between the olive oil and the SDA component is from 3:8 to 3:2. The blending of the oil components are performed to achieve optimal omega-3 and protection against oxidation. The mixing of olive oil and the SDA component is made by standardized oil blending procedures.

20 Use:

The edible lipid composition according to the present invention comprises the omega-3 fatty acid stearidonic acid (SDA) in high amounts in combination with olive oil, wherein the olive oil increases the absorption of the SDA in the body and thus conversion of SDA to EPA and DHA.

25

EPA has anti-inflammatory effects. Studies have suggested that EPA has superior lipid management properties, lowering cholesterol and contributing to heart and cardiovascular health. EPA is also thought to have strong neuro-protective properties, positively affecting mental conditions such as schizophrenia,
30 depression and overall mood. Recent studies suggest that when used in combination, EPA boosts the effectiveness of proven blockbuster drugs.

Also, EPA and DHA will lower triglyceride levels and high triglyceride content can lead to type II diabetes and raise the risk of heart disease, while only EPA

35 increases good HDL cholesterol and lowers bad LDL cholesterol.

Further, it is known in the art that intake of long chained omega-3 polyunsaturated fatty acids may reduce the risk of developing cancer (not alpha-linolenic acid - ALA), such as breast cancer, by up to 14%

- 5 Thus, EPA and DHA are known to reduce or prevent the risk of develop atherosclerosis, thrombosis, and other cardiovascular diseases as well as other inflammatory diseases such as psoriasis, diabetes, arthritis, cancer, osteoporosis and asthma. Omega-3 fatty acids reduce the growth rate of atherosclerosis plaque and therefore have inflammatory reducing quality and characteristics, since
- 10 injuries in the atherogenic process are mediated by pro-inflammatory reactions.

Thus in an aspect of the invention, the edible lipid composition is used in administration to an animal or human for preventing or reducing the risk of developing cardiovascular diseases, coronary thrombosis, atherosclerosis, cancer,

15 diabetes (especially diabetes II), alzheimers, arthritis, rheumatism, osteoporosis, psoriasis or asthma.

The lipid composition according to the present invention may be used as a supplement to the regular diet or as a component in a diet, e.g. as a component

20 in an oil-in-water or water-in-oil emulsion in food products.

The edible lipid composition may be incorporated into various food products, which incorporation may be achieved by for example emulsification by homogenization or by using an encapsulation technique, such as

25 microencapsulation. The microencapsulation may be obtained by for example spray drying and freezing. By microencapsulation oil drops are encapsulated inside a protein-carbohydrate matrix that protects the oil and creates a dry dispersible powder. By the emulsification method, small oil droplets are dispersed in the food product. The lipid composition may also be encapsulated in gelatine

30 capsules which will enhance the organoleptic properties of the oil when swallowing. However, gelatine capsules are not suitable to be ingested by vegetarians or vegans.

In a preferred embodiment, the edible lipid composition according to the present

35 invention is used in enriching food product with omega-3 fatty acids. The lipid

composition may be incorporated into a range of foods, including milk based products, drinkable yoghurts, chocolate, breakfast cereals, and food bars.

In an embodiment of the invention relates to the use of the edible lipid

5 composition according to the present invention as an ingredient in food products.

For example, the lipid composition according to the present invention may be used for enriching chocolate with omega-3 fatty acids. Thus, the present invention also relates to use of the edible lipid composition as an ingredient in chocolate.

10

The lipid composition may also be used in food bars, where the lipid composition is incorporated as an omega-3 supplement to the regular diet. Lean fish products can be enriched with the lipid composition to achieve properties as fat fish products.

15

It should be noted that embodiments and features described in the context of one of the aspects of the present invention also apply to the other aspects of the invention.

20 The invention will now be described in further details in the following non-limiting examples.

Examples

Example 1- Composition comprising SDA oil and olive oil

25

In the below table, different lipid compositions according to the present invention are shown. The lipid compositions all comprises an SDA oil and an olive oil.

Table 1. Different lipid compositions comprising SDA oil and olive oil

Recipe	SDA oil (%-wt)	Olive oil (%-wt)	Alga oil (%-wt)	Omega-3 ethylesters (%-wt)
A	90	10		0
B	70	25	5	
C	70	25		5

D	70	25	2.5	2.5
---	----	----	-----	-----

The SDA oil used comprises the fatty acid profile mentioned below in table 2.

Table 2. Fatty acid profile of SDA oil

Fatty acid		% by weight (%-wt)
Oleic acid		12-15
Linoleic acid (LA)		12-15.5
Alpha-linolenic acid (ALA)		25-32.5
Gamma- linolenic acid (GLA)		8-12
Stearidonic acid (SDA)		10-12
Other fatty acids		12-14

- 5 The olive oil used is an extra virgin olive comprising the fatty acid profile mentioned in table 3:

Table 3. Fatty acid profile of olive oil

Fatty acids	Amount (%)
Myristic acid	0.01-0.02
Palmitic acid	10-15
Palmitoleic acid	0.9-2
Stearic acid	3-3.2
Oleic acid	60-66
Linoleic acid	5-10
Linolenic acid	0.6-0.7
Other fatty acids	5

The olive oil used comprises 400 mg polyphenols per kg olive oil.

10

The compositions A, B,C, and D are prepared by mixing the SDA oil with the olive oil and further oil by standardized oil blending procedures

15

Example 2 – Composition comprising SDA concentrate and olive oil.

In the below table different lipid compositions according to the present invention comprising an SDA concentrate and olive oil are shown.

5 *Table 4. Different lipid compositions comprising SDA concentrate and olive oil*

Recipe	SDA concentrate (%-wt)	Olive oil (%-wt)	Alga oil (%-wt)	Omega-3 ethylesters (%-wt)
E	70	30	0	0
F	55	40	5	
G	55	40	0	5

The olive oil used is the same as in example 1, and the SDA concentrate comprises about 60% SDA (60 g SDA per 100 gram)

- 10 The compositions E to G is prepared by mixing the SDA concentrate with the olive oil by standardized oil blending prosedures

Example 3 – Amount of SDA, EPA; DHA and polyphenols in lipid compositions

- 15 In the lipid composition described in A, B, F and G in example 1 and 2 above is the SDA and polyphenol content measured and given in table 5 below. Further, the EPA, DHA and DPA converted from the SDA is shown.

Table 5. Amounts of various components

Recipe	SDA (g/100 ml)	EPA (g/100 ml)	DHA (g/100 ml)	DPA (g/100 ml)	Omega-3 (g/100 ml)	Polyphenols (mg/100 ml)
A	9.1	3.4	1.7	0.6	5.6	40.0
B	7.3	4.4	2.2	0.7	7.4	100.0
F	40.0	3.4	1.9	0.6	6.4	160.0
G	20.5	4.8	2.4	0.8	7.9	160.0

Example 4 – Comparison of different ratios between SDA oil and olive oil

- 5 Different lipid compositions was prepared as described in example 1 or 2 above where an SDA oil comprising 25% SDA and an olive oil comprising 400 mg/kg polyphenol was used, but where the ratio between SDA oil and olive oil varies.

- Below in table 6 is shown the amount of SDA oil and olive oil in different lipid compositions. Further, the EPA and DHA which is obtained from the lipid composition after conversion of SDA is given. Also, the polyphenol content in the lipid composition is given.
- 10

Table 6. Amounts of various components

SDA	SDA (%)	Olive oil (%)	Total omega -3 (%)	EPA (%)	DPA (%)	DHA (%)	Polyphenols (mg(kg)
I	5	95	0.44	0.26	0.04	0.013	380
II	10	90	0.88	0.53	0.09	0.26	360
III	20	80	1.75	1.05	0.18	0.53	320
IV	30	70	2.63	1.58	0.26	0.79	280
V	40	60	3.50	2.10	0.35	1.05	240
VI	45	55	3.38	2.03	0.34	1.01	220
VII	50	50	3.75	2.25	0.38	1.13	200
VII	60	40	4.50	2.70	0.45	1.35	160

VIII	70	30	4.38	2.63	0.44	1.31	120
IX	80	20	5.00	3.00	0.50	1.50	80

The conversion rate of SDA to EPA and DHA is increased the more polyphenol is present in the lipid composition.

5 Example 5 – Comparison of different amounts of SDA present in the SDA oil

Different lipid compositions was prepared as described in example 1 or 2 above having 50% of an SDA oil and 50% of an olive oil, the olive oil comprising 400 mg/kg polyphenol and where lipid compositions varies in the amount of SDA present in the SDA oil. Below in table 7 is shown the amount of SDA oil, the amount of SDA present, and the amount of olive oil in different lipid compositions. Further, the EPA and DHA which is obtained by the lipid composition after conversion of SDA is given. Also, the polyphenol content in the lipid composition is given.

15

Table 7. Amounts of various components

SDA	SDA present in SDA oil (%)	SDA oil (%)	Olive oil (%)	Total omega-3 (%)	EPA (%)	DPA (%)	DHA (%)	Polyphenols (mg(kg))
I	3	50	50	0.38	0.23	0.04	0.11	200
II	5	50	50	0.63	0.38	0.06	0.19	200
III	7	50	50	0.88	0.53	0.09	0.26	200
IV	10	50	50	1.25	0.75	0.13	0.38	200
V	12	50	50	1.5	0.90	0.15	0.45	200

Example 6 – Comparison of different amounts of polyphenols present in the olive oil

20

Different lipid compositions was prepared comprising 50% SDA oil having a 25% SDA content and 50% olive oil. The compositions was prepared as described in

example 1 or 2 above. Below in table 8 is shown the amount of SDA oil and olive oil in different lipid compositions. Further, the polyphenol content in the lipid compositions used are shown. Further, the EPA and DHA which is obtained by the lipid composition after conversion of SDA is given. Also, the polyphenol content in
5 the lipid composition is given.

Table 8. Amounts of various components

	polyphenol present in olive oil (mg/kg)	SDA oil (%)	Olive oil (%)	Total omega-3 (%)	EPA (%)	DPA (%)	DHA (%)	Polyphenols (mg/kg)
I	100	50	50	1.2	0.7	0.12	0.36	50
II	200	50	50	1.5	0.9	0.15	0.45	100
III	300	50	50	1.8	1.1	0.18	0.54	150
IV	400	50	50	2.1	1.3	0.21	0.63	200
V	500	50	50	2.4	1.4	0.24	0.72	250

The conversion rate of SDA to DHA and EPA is increased the more polyphenols are present in the olive oil.

10

Example 7 – Comparison of different lipid compositions according to the invention

Different lipid compositions was prepared comprising 50% olive oil, different amounts of SDA oil (30% or 40%), and different amounts of alga oil, wherein the
15 SDA oil comprises 25% SDA. The compositions was prepared as described in example 1 or 2 above. Below in table 9, the amount of SDA oil and olive oil in different lipid compositions is shown. Further, the polyphenol content in the lipid compositions are shown. Further, the EPA and DHA which is obtained by the lipid composition after conversion of SDA is given. The amount of polyphenol in the
20 olive oil in 400 mg/kg.

The amount of SDA in the SDA oil is 25%.

Table 9. Amounts of various components

	SDA oil (%)	Olive oil (%)	Algae oil (%)	EPA + Omeg a concen trate	Total omega -3 (%)	EPA (%)	DPA (%)	DHA (%)	Polyphe (mg(k
VI	40	50	10	0	8.50	5.10	0.85	2.55	200
VII	30	50	20	0	13.88	8.33	1.39	4.16	200
VIII	40	50	0	10	11.50	6.90	1.15	3.45	200
IX	30	50	0	20	19.88	11.93	1.99	5.96	200

5

The Algae oil used comprises about 60% EPA + DHA

Example 8 – Oxidative stability test of olive oil with polyphenols

- 10 The effect of olive oil comprising polyphenols on oxidative stress of long chain fatty acids has been analysed. Two oil mixes has been made,
 A) one oil mix comprising an oil with omega-3 fatty acids and vitamin E and
 B) a second oil mix comprising the same oil with omega-3 fatty acids as in a) in combination with an olive oil having a content of polyphenols of 400 mg/kg.

15

The oxidation stability of both oil mixes A) and B) have been analysed by the oil stability index (OSI), which is a method determining the relative resistance of fats and oils to oxidation.

- 20 In figure 1 is the oxidative stability of both oil mixes shown.

From figure 1, it is shown that addition of an olive oil comprising polyphenols will increase the oxidative stability of an oil comprising omega-3 fatty acids, ie. the omega-3 long chain fatty acids, (EPA and DHA) in the oil is protected against oxidation. Figure 1 shows that a the mixture of omega-3 fatty acid oil and olive oil

- 25 are clearly more stable (35 hours) against lipid oxidation than an omega-3 fatty

acid oil without olive oil, but stabilized with vitamin E (tocopherol) (16 hours).

Thus, there is a synergistic protective effect of polyphenols on oxidative unstable long chain polyunsaturated fatty acids.

- 5 Since all fats and oils are prone to oxidation, a vegetable oil comprising Stearidonic acid (SDA) is also prone to oxidation. Thus, the antioxidative effect of polyphenols in olive oil will also occur on SDA oil and on EPA and DHA inside our body.

Claims

1. An edible lipid composition comprising olive oil and a stearidonic acid component (SDA component), wherein said SDA component comprises stearidonic acid (SDA) in an amount of at least 6% by weight and wherein said olive oil
5 comprises polyphenols in an amount of at least 250 mg per kg olive oil and wherein the ratio between the olive oil and the SDA component is from 3:8 to 3:2.
2. The edible lipid composition according to claim 1, wherein the lipid composition comprises one or more further oil.
- 10 3. The edible lipid composition according to claim 2, wherein the further oil is an alga oil or ethylesters of EPA and/or DHA.
4. The edible lipid composition according to any of the preceding claims, wherein
15 olive oil is present in an amount of at least 25%.
5. The edible lipid composition according to any of the preceding claims, wherein the SDA component is present in an amount of at least 30% by weight.
- 20 6. The edible lipid composition according to any of the preceding claims, wherein the SDA component comprises SDA in an amount of at least 10% by weight.
7. The edible lipid composition according any of the preceding claims, wherein the lipid composition comprises SDA in an amount of at least 3 g SDA per 100 ml lipid
25 composition.
8. The edible lipid composition according to any of the preceding claims, wherein the SDA component comprises GLA in an amount of at least 5% by weight .
- 30 9. The edible lipid composition according to any of the preceding claims, wherein the SDA component comprises linoleic acid (LA) in amount below 10% by weight.

10. The edible lipid composition according to any of the preceding claims, wherein the lipid composition comprises oleic acid in an amount of at least 10% by weight.
- 5 11. The edible lipid composition according to any of the preceding claims, wherein the olive oil comprises polyphenol in the range of 0.025 to 1% by weight.
12. An edible lipid composition according to any of the preceding claims, wherein the olive oil comprises squalene in an amount of at least 200 mg/kg.
- 10 13. An edible lipid composition according to any of the preceding claims, wherein the SDA component is not Hemp seed oil.
14. A method of preparing the lipid composition according to any of the claims 1 to 13, wherein the method comprising mixing of an olive oil comprising polyphenols in an amount of at least 250 mg per kg olive oil and a SDA component comprising at least 4%6% stearidonic acid and optionally a further oil.
- 15 15. The edible lipid composition according to any of claims 1 to 13 for use in administration to an animal or human for preventing or reducing the risk of developing cardiovascular diseases, coronary thrombosis, atherosclerosis, cancer, diabetes, rheumatism, alzheimers, arthritis, rheumatism, osteoporosis, psoriasis or asthma.
- 20

1/1




Fig. 1

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2014/071418

A. CLASSIFICATION OF SUBJECT MATTER INV. A23D9/00 A23D9/007 A23L1/30 A23K1/16 A23D9/013 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A23D A23L A23K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, BIOSIS, COMPENDEX, FSTA, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AU 2012 100 994 A8 (HINSON BRIAN) 2 August 2012 (2012-08-02) the whole document -----	1-15
X	US 2009/099261 A1 (BELL STACEY JANE [US] ET AL) 16 April 2009 (2009-04-16) example 6 -----	15
A	US 2012/231142 A1 (LUCAK CANDICE [US] ET AL) 13 September 2012 (2012-09-13) paragraph [0022]; examples 5,10 -----	1-15
A	WO 2008/085841 A1 (MONSANTO TECHNOLOGY LLC [US]; WILKES RICHARD S [US]) 17 July 2008 (2008-07-17) claim 89 ----- -/-	1-15
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 15 January 2015		Date of mailing of the international search report 21/01/2015
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Saettel, Damien

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2014/071418

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 696 453 A2 (CLINTEC NUTRITION CO [US]) 14 February 1996 (1996-02-14) example 3 -----	1-15
A	US 2007/207223 A1 (DIRIENZO MAUREEN A [US] ET AL) 6 September 2007 (2007-09-06) claims -----	15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2014/071418

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
AU 2012100994	A8	02-08-2012	NONE
US 2009099261	A1	16-04-2009	NONE
US 2012231142	A1	13-09-2012	CA 2767396 A1 20-01-2011 CN 102469826 A 23-05-2012 EP 2453766 A2 23-05-2012 US 2012231142 A1 13-09-2012 WO 2011008946 A2 20-01-2011
WO 2008085841	A1	17-07-2008	AR 064743 A1 22-04-2009 AU 2008203870 A1 17-07-2008 BR PI0806335 A2 06-09-2011 CA 2673942 A1 17-07-2008 CN 101677589 A 24-03-2010 EP 2117335 A1 18-11-2009 IL 199650 A 31-12-2013 JP 2010516230 A 20-05-2010 KR 20090094868 A 08-09-2009 NZ 578166 A 27-04-2012 US 2010021608 A1 28-01-2010 WO 2008085841 A1 17-07-2008
EP 0696453	A2	14-02-1996	CA 2150741 A1 18-12-1995 EP 0696453 A2 14-02-1996 JP H08169824 A 02-07-1996
US 2007207223	A1	06-09-2007	AR 059720 A1 23-04-2008 BR PI0708535 A2 31-05-2011 CA 2644154 A1 13-09-2007 CN 101437508 A 20-05-2009 EP 1991217 A2 19-11-2008 JP 2009529044 A 13-08-2009 US 2007207223 A1 06-09-2007 WO 2007103160 A2 13-09-2007